Alvotech shares rise after FDA accepts review for Crohn’s drug
Alvotech shares rose after the FDA accepted AVT80 for review for a Crohn’s treatment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.